Cardiorentis raises $60M as PhIII heart failure trial nears completion

Nick Paul Taylor

has raised CHF 60 million ($ 60 million). The investment bolsters the biotech's bank balance at a time when it is nearing the end of a Phase III of its drug for acute decompensated , data from which are due to be submitted to regulators later this year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS